Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a new coronavirus discovered in 2019, resulted in the COVID-19 pandemic ( 1). The identification of specific IgG+ RBD+ MBCs by flow cytometry provides information on different humoral immune response outcomes in patients with IEI and aids the assessment of immune competence status after SARS-CoV-2 mRNA vaccine (BNT162b2), together with S-specific IgG antibodies and T-cell responses. Lastly, we observed a profound failure of B and T-cell response in 3 (10%) patients with IEI, with no assessment of S-specific IgG antibodies, IgG+ RBD+ MBCs, and negative cellular response. Despite the presence of S-specific IgG antibodies, we were unable to detect a relevant percentage of IgG+ RBD+ MBCs in 5/25 however, all presented positive T-cell response. We detected various patterns among the patients with IEI with circulating B cells (25, 81%): an adequate humoral response was observed in 12/25, consider by the detection of positive S-specific IgG antibodies and the presence of specific IgG+ RBD+ MBCs, presenting a positive T-cell response in 4/25, very low S-specific IgG antibody counts correlated with undetectable events in the IgG+ RBD+ MBC compartment but with positive cellular response. Within the control group, there was an increase in the percentage of specific IgG+ RBD+ MBCs 21 days after the second dose, which was consistent with S-specific IgG antibodies.Thirty-one patients with IEI were included for the pre- and post-vaccination study IgG+ RBD+ MBCs were not evaluated in 6 patients due to an absence of B cells in peripheral blood. Results and discussion: We first analyzed the percentage of specific RBD+ IgG+ MBCs in healthy healthcare workers. Methods: The aim of this study was to determine the humoral responses of patients with IEI through a comprehensive analysis of specific receptor-binding domain-positive (RBD+) IgG+ memory B cells (MBCs) by flow cytometry, together with routine S-specific IgG antibodies and QuantiFERON SARS-CoV-2 (T-cell response), before the vaccine and 3 weeks after a second dose. Estimating the immune competence of immunocompromised patients for an infection risk assessment or after SARS-CoV-2 vaccination constituted a challenge. Introduction: Inborn errors of immunity (IEI) are a heterogeneous group of diseases caused by intrinsic defects of the immune system. 7HIV Unit, Internal Medicine Department, La Paz University Hospital, AIDS and Infectious Diseases Group, Center for Biomedical Network Research on Infectious Diseases (CIBERINFEC CB9), La Paz Institute for Health Research (IdiPAZ), Madrid, Spain.
1Center for Biomedical Network Research on Rare Diseases (CIBERER U767), ISCIII, Madrid, Spain.González-García 7, Miguel González-Muñoz 3, Rebeca Rodríguez-Pena 1,2,3 and Eduardo López Granados 1,2,3*
Lucía del Pino Molina 1,2*†, Luz Yadira Bravo Gallego 1,2†, Pilar Nozal 3,4,5†, Yolanda Soto-Serrano 2, Ana Martínez-Feito 3,6, Keren Reche-Yebra 2, Andrea González-Torbay 3, Ricardo Cuesta-Martín de la Cámara 3, Carla Gianelli 2,3, Carmen Cámara 2,3, J.
0 kommentar(er)
